Top Page
AbbVie
(NYSE:ABBV)
AbbVie (ABBV) vs. SPDR S&P 500 ETF (SPY)
AbbVie Business Overview & Revenue Model
AbbVie Key Performance Indicators (KPIs)
Analyzes revenue from different business segments, highlighting which areas drive growth and profitability, and indicating strategic focus or diversification.
Main Street DataAbbVie Earnings Call Summary
AbbVie Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 59.64B | 56.33B | 54.32B | 58.05B | 56.20B | 45.80B |
| Gross Profit | 45.45B | 39.43B | 33.90B | 40.64B | 38.75B | 30.42B |
| EBITDA | 12.72B | 14.91B | 17.17B | 24.17B | 23.93B | 12.32B |
| Net Income | 2.39B | 4.28B | 4.86B | 11.84B | 11.54B | 4.62B |
Balance Sheet | ||||||
| Total Assets | 133.90B | 135.16B | 134.71B | 138.81B | 146.53B | 150.56B |
| Cash, Cash Equivalents and Short-Term Investments | 5.67B | 5.55B | 12.82B | 9.23B | 9.83B | 8.48B |
| Total Debt | 68.74B | 67.84B | 60.12B | 64.19B | 77.58B | 87.06B |
| Total Liabilities | 136.50B | 131.80B | 124.31B | 121.52B | 131.09B | 137.47B |
| Stockholders Equity | -2.64B | 3.33B | 10.36B | 17.25B | 15.41B | 13.08B |
Cash Flow | ||||||
| Free Cash Flow | 20.57B | 17.83B | 22.06B | 24.25B | 21.99B | 16.79B |
| Operating Cash Flow | 20.86B | 18.81B | 22.84B | 24.94B | 22.78B | 17.59B |
| Investing Cash Flow | -7.05B | -20.82B | -2.01B | -623.00M | -2.34B | -37.56B |
| Financing Cash Flow | -15.42B | -5.21B | -17.22B | -24.80B | -19.04B | -11.50B |
AbbVie Technical Analysis
AbbVie Risk Analysis
AbbVie Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $472.05B | 18.91 | 33.62% | 2.59% | 5.08% | 71.07% | |
78 Outperform | $230.63B | 12.29 | 39.51% | 3.49% | 1.59% | 58.02% | |
76 Outperform | $127.00B | 12.96 | 8.39% | 4.24% | -9.32% | 120.62% | |
75 Outperform | $276.07B | 29.36 | 21.73% | 1.76% | 12.95% | 44.28% | |
68 Neutral | $142.48B | 14.61 | 10.59% | 6.86% | 4.44% | 128.96% | |
62 Neutral | $410.67B | 175.33 | 138.53% | 3.01% | 7.40% | -53.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
AbbVie Corporate Events
AbbVie’s latest earnings call paints a picture of robust performance and optimism for the future. The company reported significant growth in key therapeutic areas such as immunology and neuroscience, exceeding financial expectations and raising its full-year outlook. Despite facing challenges in the aesthetics segment and the erosion of Humira sales due to biosimilar competition, AbbVie’s strong pipeline and increased R&D investment suggest a positive long-term outlook.
AbbVie is currently conducting a Phase 1 clinical study titled ‘A Phase 1, Double-blind, Placebo-controlled, First-in-human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ABBV-1042 in Healthy Subjects.’ The study aims to assess the adverse events, tolerability, and pharmacokinetics of oral ascending doses of ABBV-1042 in healthy adult participants. This research is significant as it represents the initial human trials for ABBV-1042, potentially paving the way for future therapeutic developments.
AbbVie recently updated its clinical study titled ‘A Phase 1 Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088.’ The study aimed to evaluate the safety, tolerability, and pharmacokinetics of ABBV-1088 in healthy adult Western, Han-Chinese, and Japanese participants. It also assessed the drug-drug interaction between itraconazole and ABBV-1088 in Western participants, marking a significant step in understanding the drug’s potential.
AbbVie recently updated its clinical study titled A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Budigalimab and/or ABBV-382 in People Living With HIV on Stable Antiretroviral Therapy Undergoing Analytical Treatment Interruption. The study aimed to assess changes in disease activity, adverse events, and drug pharmacokinetics in HIV patients. This research is significant as it explores potential new treatments for HIV, a chronic condition requiring lifelong therapy.
AbbVie is currently conducting a study titled A Prospective, Open-Label Study to Evaluate Subject Satisfaction With Overall Facial Appearance After Treatment With JUVÉDERM® Products in Medical Weight Loss (MWL) Subjects. The primary aim is to assess the safety and effectiveness of JUVÉDERM products in adults looking to enhance facial volume and skin quality. This study is significant as it addresses aesthetic concerns in individuals experiencing mid-face volume deficit.
AbbVie is currently conducting a study titled ‘Mass Balance Study of [14C] ABBV-1354 (Icalcaprant) in Healthy Male Subjects Following Single Oral Dose Administration.’ The study aims to assess the mass balance of the drug ABBV-1354 in healthy adult male participants. This research is significant as it contributes to understanding the drug’s absorption, distribution, metabolism, and excretion in the human body.
AbbVie is conducting a Phase 1 study titled ‘A Phase 1, Randomized, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Emraclidine Following Multiple Ascending Oral Doses in Healthy Elderly Subjects.’ The study aims to assess how the drug emraclidine moves through the body and its safety and tolerability in healthy elderly participants. This is significant as it could lead to new therapeutic options for age-related conditions.
Study Overview: AbbVie is conducting a study titled A Multicenter, Cohort-design, Double-blind, Randomized, Parallel-group, Controlled Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars. The study aims to assess the safety and effectiveness of ELAPR002f injectable gel in treating atrophic acne scars, which significantly impact individuals’ quality of life.
Study Overview: AbbVie is conducting a Phase 2 study titled A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification. The study aims to assess adverse events and changes in disease activity in participants aged 12 and older with MET amplification in solid tumors. This research is significant as it targets a specific genetic alteration in cancer, potentially offering new treatment avenues.
AbbVie is conducting a study titled ‘Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of ABBV-6628 in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration.’ The study aims to evaluate the safety and movement of the drug ABBV-6628 in the bodies of adults with geographic atrophy, a severe form of age-related macular degeneration. This research is significant as it could lead to new treatment options for this debilitating eye condition.
AbbVie recently completed a clinical study titled A 52-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Subjects With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder. The study aimed to assess the long-term safety and tolerability of cariprazine, a drug intended to treat pediatric patients with these conditions, establishing its benefit-risk profile.
AbbVie recently updated its clinical study titled, A Phase 1 First-in-Human, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABBV-303, as Monotherapy and in Combination With Budigalimab (ABBV-181), in Adult Subjects With Advanced Solid Tumors. The study aims to assess the safety and efficacy of ABBV-303, both alone and with Budigalimab, for treating advanced solid tumors. This research is significant as it explores new treatment avenues for challenging cancer types.
AbbVie recently updated its clinical study titled ‘A Phase 1 b Randomized, Double-blind, Placebo-Controlled, Experimental Medicine Study of Fosigotifator in Adults With Major Depressive Disorder.’ The study aimed to assess the safety and effectiveness of fosigotifator, a new treatment for major depressive disorder (MDD), a serious mood disorder affecting emotional and physical health.
Study Overview: AbbVie recently announced a study titled A Prospective, Single-Arm, Descriptive Observational Study to Evaluate Changes in Hair in Women Exposed to Oriahnn®. The study aims to assess the incidence and characteristics of hair loss in women taking Oriahnn for heavy menstrual bleeding associated with uterine fibroids. This research is significant as it addresses a common side effect that could impact patient quality of life and treatment adherence.
AbbVie has recently provided an update on its Phase 3 clinical study titled A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine After Allogeneic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia (AML) (VIALE-T). The study aimed to assess the efficacy of venetoclax combined with azacitidine to improve overall survival in AML patients post-transplantation, compared to best supportive care.
Study Overview: AbbVie recently updated its clinical study titled ‘Prospective Registry to Evaluate Pregnancy Outcomes in Women Treated With Elagolix.’ This study aims to assess maternal, fetal, and infant outcomes in women exposed to Elagolix, a drug used for endometriosis and uterine fibroids, compared to those not exposed. The study’s significance lies in understanding the potential risks associated with Elagolix during pregnancy.
Study Overview: AbbVie is conducting a multicenter, open-label study titled ‘Multicenter, Open-label Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects With Depressive Episodes Associated With Bipolar I or II Disorder.’ The study aims to assess the safety and effectiveness of ABBV-932, an investigational drug, in treating depressive episodes in adults with bipolar I or II disorder. This research is significant as bipolar disorder affects up to 4% of the adult population in the U.S.
AbbVie has completed a Phase 3 clinical study titled ‘A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis.’ The study aimed to assess the efficacy and safety of upadacitinib for treating moderate to severe atopic dermatitis in adolescents and adults who are candidates for systemic therapy.
AbbVie recently completed a Phase 3 clinical study titled A Phase 3, Multicenter, Open-Label 156-Week Extension Study To Evaluate The Long-Term Safety And Tolerability Of Oral Atogepant For The Prevention Of Migraine In Participants With Chronic Or Episodic Migraine. The study aimed to assess the long-term safety and tolerability of Atogepant, a drug intended to prevent migraines in individuals suffering from chronic or episodic conditions. This research is significant as it addresses the need for effective long-term migraine prevention strategies.
AbbVie recently completed a Phase 2 clinical study titled A Phase 2 Study of the Safety and Efficacy of Venetoclax in Combination With Obinutuzumab or Ibrutinib in Japanese Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). The study aimed to evaluate the effectiveness and safety of venetoclax when combined with either obinutuzumab or ibrutinib in Japanese patients with untreated CLL/SLL, a significant concern given the lower incidence of CLL/SLL in Japan compared to Western countries.
AbbVie recently completed a clinical study titled ‘A Bioavailability and Food Effect Study of Venetoclax New Tablet Formulation 2.0 in Healthy Female Subjects.’ The study aimed to evaluate the bioavailability of a new venetoclax tablet formulation under high-fat conditions and assess potential food effects on its bioavailability. This study is significant as it could lead to improved drug formulations, enhancing patient outcomes.
AbbVie has recently completed a Phase 2 study titled A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Budigalimab and/or ABBV-382 in People Living With HIV on Stable Antiretroviral Therapy Undergoing Analytical Treatment Interruption. The study aimed to assess changes in disease activity, adverse events, and drug pharmacokinetics in adults with HIV. This research is significant as it explores potential new treatments for a chronic condition requiring lifelong therapy.
Study Overview: AbbVie recently completed a study titled A Study to Assess the Effect of Food on ABBV-101 Pharmacokinetics When Administered as an Oral ABBV-101 Tablet Formulation in Healthy Volunteers. The study aimed to understand how a high-fat meal affects the movement of the drug ABBV-101 through the body, which is crucial for optimizing its administration and effectiveness.
AbbVie recently completed a Phase 1 clinical study titled ‘A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors.’ The study aimed to evaluate the safety and efficacy of the investigational drug ABBV-CLS-579, both as a monotherapy and in combination with other agents, for treating advanced solid tumors. This study is significant as it seeks to establish a safe and effective dosage for ABBV-CLS-579, potentially offering new treatment options for patients with difficult-to-treat cancers.
AbbVie is currently conducting a two-part clinical study titled ‘A Two-Part First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Subcutaneous Doses of GUB014295 in Lean to Overweight or Obese But Otherwise Healthy Men and Women.’ The primary goal is to evaluate the safety and tolerability of GUB014295, a long-acting amylin analogue, with secondary objectives focusing on its pharmacokinetics and pharmacodynamics. This study is significant as it aims to explore potential treatments for overweight conditions in otherwise healthy individuals.
AbbVie, in collaboration with Ironwood Pharmaceuticals, has completed a Phase 3 study titled A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation. The study aimed to evaluate the safety and efficacy of linaclotide, an oral drug, in treating functional constipation in young children, a condition with no currently approved pharmacological treatments.
AbbVie has recently completed a clinical study titled ‘Prospective Observational Cohort Study of Patients With Moderate to Severe Chronic Plaque Psoriasis in Taiwan.’ The primary goal of this study was to evaluate the durability of response of the drug risankizumab compared to other biologics, using the Psoriasis Area and Severity Index (PASI) 90 response as a measure. This study is significant as it aims to improve long-term health outcomes and quality of life for individuals with moderate to severe chronic plaque psoriasis.
AbbVie is conducting a Phase 1 clinical study titled A Phase 1 Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088. The study aims to evaluate the safety, tolerability, and pharmacokinetics of ABBV-1088 in healthy adults, including Western, Han-Chinese, and Japanese participants. It also examines the drug-drug interaction between ABBV-1088 and itraconazole in Western participants, which is crucial for understanding the compound’s potential in diverse populations.
On September 11, 2025, AbbVie announced a settlement with all generic manufacturers regarding the generic versions of its drug RINVOQ, delaying generic entry in the U.S. until April 2037, assuming pediatric exclusivity is granted. This settlement potentially strengthens AbbVie’s market position by extending its exclusivity period, impacting stakeholders by delaying generic competition and maintaining market share for RINVOQ.
The most recent analyst rating on (ABBV) stock is a Hold with a $228.00 price target. To see the full list of analyst forecasts on AbbVie stock, see the ABBV Stock Forecast page.
Study Overview: The MAVRiC Study, officially titled ‘A Phase II Study of Disease Risk Mutation Guided Finite Duration Acalabrutinib Plus Venetoclax for Relapse in CLL/SLL After First-line Finite Covalent BTKi Plus BCL2i Combination, With or Without Obinutuzumab,’ aims to evaluate the efficacy and safety of acalabrutinib plus venetoclax in patients with relapsed Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). This study targets patients who have previously responded to first-line therapy and maintained a response for at least two years.
AbbVie is conducting a first-in-human study titled ‘A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies’ to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-525 in adults with B-cell malignancies. This study is significant as it targets cancers of B lymphocytes, which are crucial in fighting infections.
AbbVie is conducting a Phase 2 study titled A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects With Generalized Anxiety Disorder Who Have Had an Inadequate Response to Antidepressant Therapies. The study aims to assess the safety and efficacy of ABBV-932 when added to existing antidepressant therapies in adults with generalized anxiety disorder (GAD) who have not responded adequately to standard treatments.
AbbVie is conducting a significant clinical study titled ‘A Phase 2/3 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)’. The study aims to determine the optimal dose and assess the safety and efficacy of ABBV-706 when combined with atezolizumab, compared to the standard of care treatments in patients with extensive stage small cell lung cancer.
AbbVie is conducting a clinical study titled Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI. The study aims to evaluate the adverse events and changes in disease activity associated with the investigational drug telisotuzumab adizutecan, compared to the standard of care in treating non-small cell lung cancer (NSCLC).
AbbVie is currently conducting a clinical study titled ‘A First-in-Human Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Subjects.’ The study aims to assess the safety and pharmacokinetic properties of ABBV-277, a new drug candidate, in healthy adults. This research is significant as it marks the initial step in understanding the drug’s potential therapeutic benefits.
AbbVie is currently conducting a study titled ‘A Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Chinese Subjects.’ The primary objective is to assess adverse events, tolerability, and the pharmacokinetics of oral doses of ABBV-932 in healthy adult Chinese participants. This study is significant as it aims to ensure the safety and efficacy of ABBV-932, a potential new drug candidate.
AbbVie is conducting a Phase 3 study titled A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Alopecia Areata and at Least 25% Scalp Hair Loss. The study aims to assess the safety, effectiveness, and tolerability of upadacitinib in Japanese adolescents and adults with severe alopecia areata, a condition where the immune system attacks hair follicles causing hair loss.
AbbVie’s latest clinical study, officially titled ‘AndroMETa-CRC-064,’ aims to evaluate the safety and effectiveness of telisotuzumab adizutecan (ABBV-400) compared to the current standard treatment of LONSURF combined with bevacizumab in adults with refractory metastatic colorectal cancer expressing high levels of c-Met protein. This study is significant as colorectal cancer is a leading cause of cancer-related deaths globally, and finding more effective treatments could improve patient outcomes.
AbbVie is conducting a Phase 3 clinical study titled A Phase 3 Multicenter Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Upadacitinib With Open-Label Induction, Randomized, Double-Blind Maintenance and Open-Label Long-Term Extension in Pediatric Subjects With Moderately to Severely Active Crohn’s Disease and Inadequate Response, Intolerance, or Medical Contraindications to Corticosteroids, Immunosuppressants, and/or Biologic Therapy. The study aims to assess the safety and effectiveness of Upadacitinib, an oral medication, in treating pediatric patients aged 2 to 18 years with moderate to severe Crohn’s Disease who have not responded adequately to other treatments.
AbbVie is currently conducting a Phase 2 clinical study titled A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer. The study aims to assess the safety and efficacy of Telisotuzumab Adizutecan, an investigational drug, in combination with other treatments for metastatic colorectal cancer (mCRC), a prevalent cancer worldwide.
AbbVie is conducting a study titled ‘A Dose Escalation and Expansion Study of Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Multiple Myeloma.’ The study aims to evaluate the safety and effectiveness of etentamig, an investigational drug, in combination with other anti-cancer treatments for adults with relapsed or refractory multiple myeloma. This research is significant as it explores new therapeutic options for a challenging condition.
AbbVie (ABBV) is conducting a Phase 1/2 clinical study titled ‘Phase 1/2 Study of Etentamig in Combination With a CELMoD Agent for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma.’ The study aims to evaluate the safety and efficacy of etentamig combined with a cereblon E3 ligase modulatory drug (CELMoD) in treating relapsed or refractory multiple myeloma (R/R MM). This study is significant as it explores new treatment avenues for a challenging condition.
Study Overview: AbbVie is conducting a multicenter, Phase 1b, open-label study titled A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects With Relapsed or Refractory Multiple Myeloma. The study aims to assess adverse events and changes in disease symptoms of ABBV-383 in adults with relapsed or refractory multiple myeloma, a challenging blood cancer. This research is significant as it explores new treatment avenues for a condition with limited options.
Study Overview: AbbVie is conducting a Phase 2 clinical study titled An Adaptive Two-part Randomized, Double Blind, Placebo-controlled Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Emraclidine in Participants With Schizophrenia. The study aims to evaluate the safety and effectiveness of Emraclidine, an investigational drug, in treating schizophrenia, a severe psychiatric disorder.
AbbVie is currently conducting a study titled ‘Effectiveness aNd Use of fosleVOdopa-foscarbidopa in Advanced Parkinson Disease in Real Life Setting’ to evaluate the effectiveness and safety of foscarbidopa/foslevodopa in adult patients with advanced Parkinson’s disease. The study aims to provide insights into the drug’s performance in a real-world setting, which is crucial for understanding its practical benefits and risks.
AbbVie (ABBV) is conducting a Phase 1 clinical study titled A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors. The study aims to assess the safety, tolerability, and preliminary efficacy of ABBV-706, alone and in combination with other drugs, in treating advanced solid tumors, including small cell lung cancer and high-grade neuroendocrine carcinomas.
Study Overview: AbbVie is conducting a study titled ‘Assessment of the Relative Bioavailability of ABBV-932 Formulations in Healthy Adult Subjects.’ The study aims to evaluate the relative bioavailability and the effect of food on the pharmacokinetics of ABBV-932, a drug administered orally to healthy adults. This research is significant as it could influence the development and optimization of ABBV-932 formulations, potentially impacting future therapeutic applications.
AbbVie is conducting a Phase 1 clinical study titled ‘A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ABBV-8736 After Multiple Ascending Doses in Healthy Adult Subjects.’ The study aims to assess the safety and tolerability of ABBV-8736, an intravenous drug, in healthy volunteers. This research is significant as it explores the drug’s movement through the body and its potential immune response, which are crucial for future therapeutic applications.
Study Overview: AbbVie is conducting a global real-world evidence study titled ‘ROSSINI: Real-world Outcomes With continuouS Subcutaneous Levodopa INfusIon’ to assess the long-term effectiveness of ABBV-951 in treating advanced Parkinson’s Disease (PD) in routine clinical practice. The study aims to evaluate how ABBV-951 impacts disease activity in adult participants, highlighting its significance in managing PD, a progressive neurological disorder.
Study Overview: AbbVie is conducting a pivotal clinical study titled ‘A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE).’ The study aims to evaluate the efficacy and safety of a novel gene therapy, RGX-314, for treating neovascular age-related macular degeneration (nAMD), a leading cause of vision loss globally. This study is significant as it explores a potentially transformative one-time treatment option for a condition that currently requires frequent and lifelong injections.
AbbVie is set to embark on a significant clinical study titled ‘A Prospective, Real-World Study Evaluating the Impact of RISankizumab on BurdEn of Disease in Ulcerative Colitis in JaPan (RISE UP).’ The primary objective is to assess the change in disease activity among Japanese participants with moderate to severe ulcerative colitis using risankizumab, a drug already approved for this condition. This study holds importance as it aims to provide real-world evidence of the drug’s effectiveness in routine clinical practice.
Study Overview: AbbVie is conducting a study titled A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism. The study aims to assess the safety and efficacy of Armour Thyroid against synthetic T4 in adults with primary hypothyroidism, focusing on dose conversion effectiveness and safety.
AbbVie is conducting a clinical study titled ‘A Prospective Observational Study of Atogepant Effectiveness in Routine Clinical Practice’ to assess the real-world effectiveness of Atogepant in treating adult participants with migraines. The study aims to provide insights into the drug’s performance outside of controlled clinical trials, offering valuable data for healthcare providers and patients.
AbbVie is conducting a Phase 3 clinical study titled ‘A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.’ The study aims to evaluate the efficacy and safety of telisotuzumab vedotin compared to docetaxel in treating non-squamous non-small cell lung cancer (NSCLC) in adults who have undergone prior treatment. This research is significant as it seeks to improve treatment outcomes for a challenging cancer type.
AbbVie’s latest clinical study, officially titled ‘A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment,’ aims to optimize dosing and assess the safety and efficacy of Livmoniplimab combined with Budigalimab in treating advanced HCC. This study is significant as HCC is a leading cause of cancer-related deaths globally.
AbbVie is conducting a Phase 3 study titled A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab With Open-Label Induction, Randomized Double-Blind Maintenance, and Open-Label Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) With Moderately to Severely Active Ulcerative Colitis. The study aims to understand how Risankizumab, a drug already approved for adults with ulcerative colitis, works in children aged 2 to 18 years. This research is significant as it seeks to expand treatment options for pediatric patients suffering from this chronic condition.
Study Overview: AbbVie is conducting a study titled An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Budigalimab in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations. The study aims to assess adverse events and changes in disease activity when combining Telisotuzumab Adizutecan with Budigalimab in treating non-small cell lung carcinoma (NSCLC), a leading cause of cancer-related deaths.
AbbVie is currently conducting a pivotal Phase 3 clinical study titled ‘A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD.’ The study aims to assess the efficacy and safety of RGX-314, a novel gene therapy for neovascular age-related macular degeneration (wet AMD), which is a leading cause of vision loss. The significance of this study lies in its potential to offer a one-time treatment alternative to current therapies that require frequent injections.
AbbVie is conducting a Phase 3b clinical study titled A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Combined Oral Contraceptives in Premenopausal Women With Documented Endometriosis and Associated Moderate to Severe Pain. The study aims to assess the safety and effectiveness of elagolix, in combination with combined oral contraceptives, in treating dysmenorrhea in women with endometriosis. This condition affects a significant portion of women of childbearing age, impacting their daily lives and mental health.
AbbVie is currently conducting a Phase 2 study titled A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression. The study aims to assess the incidence and severity of ocular treatment-emergent adverse events related to mirvetuximab soravtansine and evaluate prophylactic strategies in patients with recurrent ovarian cancer exhibiting high folate receptor-alpha expression. This research is significant as it addresses potential side effects of a promising cancer treatment.
AbbVie, in collaboration with Pfizer, is conducting a clinical study titled ‘A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AZTREONAM AND AVIBACTAM ± METRONIDAZOLE IN NEONATES AND INFANTS FROM BIRTH TO LESS THAN 9 MONTHS OF AGE WITH SUSPECTED OR CONFIRMED INFECTIONS DUE TO GRAM-NEGATIVE PATHOGENS REQUIRING INTRAVENOUS ANTIBIOTIC TREATMENT’. The study aims to assess the safety and effects of the antibiotic combination aztreonam-avibactam (ATM-AVI) in treating gram-negative bacterial infections in newborns and infants.
AbbVie is currently conducting a study titled ‘Prospective Multi-country, Real-world, Multi-arm Study of Treatment PErsistence With RISankizumab in Psoriatic Arthritis (PERIS).’ The study aims to evaluate the long-term use and effectiveness of risankizumab, an approved drug for psoriatic arthritis, compared to other advanced therapies. This research is significant as it seeks to provide insights into treatment persistence in real-world settings across 15 countries, involving 900 to 1200 participants.
Study Overview: AbbVie, in collaboration with Genmab, is conducting a real-world study titled EpcoReal: A Multi-country, Prospective Observational Study of Epcoritamab in NHL Comprising Two Patient Cohorts (3L+ (D)LBCL and 3L+ FL). The study aims to evaluate the effectiveness of subcutaneous epcoritamab in treating adult participants with advanced Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL), which are types of non-Hodgkin lymphoma.
Study Overview: AbbVie is conducting a Phase 3 clinical trial titled A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age. The study aims to assess the safety and efficacy of Atogepant in preventing chronic migraines in adolescents, a significant step in addressing this debilitating condition in younger populations.
AbbVie is currently conducting a Phase 1 open-label study titled ‘A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications.’ The study aims to assess adverse events and changes in disease activity in adult participants with advanced solid tumors when treated with ABBV-400, an investigational drug. This research is significant as it targets various challenging cancer types, potentially offering new treatment avenues.
Study Overview: AbbVie, in collaboration with Genmab, is conducting a Phase 3 study titled A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. The study aims to evaluate the safety and efficacy of epcoritamab plus lenalidomide (E-Len) versus rituximab plus gemcitabine and oxaliplatin (R-GemOx) in treating adult patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL), a rare and aggressive cancer.
AbbVie is conducting a clinical study titled A Multicenter, Randomized Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Upadacitinib With a Tocilizumab Reference Arm in Subjects From 1 Year to Less Than 18 Years Old With Active Systemic Juvenile Idiopathic Arthritis. The study aims to evaluate the safety and effectiveness of upadacitinib in treating pediatric and adolescent patients with systemic juvenile idiopathic arthritis (sJIA), a severe form of arthritis affecting children. The study’s significance lies in addressing a challenging condition that can persist into adulthood.
AbbVie is currently conducting a Phase 3 clinical study titled A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis. The study aims to evaluate adverse events and changes in disease activity when comparing oral upadacitinib to subcutaneous dupilumab in pediatric patients with moderate to severe atopic dermatitis. This research is significant as it addresses the need for effective systemic treatments in younger patients who do not respond adequately to topical therapies.
AbbVie, in collaboration with Genmab, is conducting a Phase 3 clinical trial titled ‘A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)’. The study aims to assess the safety and efficacy of combining subcutaneous epcoritamab with intravenous rituximab and oral lenalidomide in treating adult participants with previously untreated follicular lymphoma, a common and incurable type of B-cell cancer.
AbbVie is conducting a Phase 2/3 study titled ‘A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer.’ The study aims to evaluate the safety, efficacy, and optimal dosage of telisotuzumab adizutecan combined with osimertinib, a standard treatment for non-small cell lung cancer (NSCLC), to improve patient outcomes.
AbbVie (ABBV) is conducting a Phase 1/2 clinical study titled ‘A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor ABBV-453 Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma.’ The study aims to assess the safety and efficacy of ABBV-453, a BCL-2 inhibitor, in treating relapsed/refractory multiple myeloma (R/R MM). This research is significant as it explores new treatment avenues for a challenging plasma cell disease.
AbbVie is conducting a Phase 1 clinical study titled ‘A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer.’ The study aims to assess adverse events and changes in disease activity when ABBV-324 is administered to adults with hepatocellular cancer (HCC) or squamous-cell non-small cell lung cancer (LUSC). This research is significant as HCC and lung cancer are among the leading causes of cancer-related deaths worldwide.
AbbVie is conducting a Phase 2 clinical study titled A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer. The study aims to evaluate the safety and efficacy of telisotuzumab vedotin, an investigational drug, in treating non-small cell lung cancer (NSCLC) by assessing changes in disease activity and adverse events.
AbbVie is conducting a study titled A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in Pediatric Subjects (10 to 17 Years of Age) in the Treatment of Depressive Episodes Associated With Bipolar I Disorder. The study aims to evaluate the change in disease state and safety of cariprazine in treating depressive episodes in pediatric patients with bipolar I disorder, addressing a gap in treatment options for this age group.
Study Overview: AbbVie is conducting a Phase 2 multicenter platform trial titled ‘A Phase 2 Multicenter Platform Trial of Targeted Immunomodulator Therapies for Moderate to Severe Atopic Dermatitis.’ The study aims to evaluate the clinical efficacy and safety of single and combination therapies for moderate to severe atopic dermatitis (AD), a skin condition causing rash and itching due to inflammation. This trial is significant as it explores new treatment avenues for AD, potentially improving patient outcomes.
AbbVie is conducting a Phase 2 study titled ‘A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)’. The study aims to assess the safety and effectiveness of the investigational drug ABBV-CLS-628 in treating ADPKD, a common genetic kidney disease characterized by fluid-filled cysts.
AbbVie is conducting a Phase 3 study titled ‘A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma.’ The study aims to assess the effectiveness of etentamig, an investigational drug, against standard therapies in treating relapsed or refractory multiple myeloma, a challenging blood cancer.
Study Overview: AbbVie is conducting a Phase 4 clinical study titled A Phase 4 Study of Venetoclax in Combination With Azacitidine in Indian Subjects With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy. The study aims to evaluate the change in disease activity and adverse events in adult participants with acute myeloid leukemia (AML) in India, who cannot undergo standard induction therapy. This research is significant as it explores alternative treatment options for a highly aggressive form of blood cancer.
AbbVie is currently conducting a Phase 2 multicenter, randomized study titled ‘A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Active Psoriatic Arthritis.’ The study aims to evaluate the efficacy and safety of targeted therapies for treating active psoriatic arthritis, focusing on changes in disease symptoms. This research is significant as it seeks to improve treatment options for a condition characterized by joint pain and swelling.
AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17). The study aims to assess the safety and effectiveness of ubrogepant, a drug approved for adults, for treating migraines in children and adolescents aged 6-17. This research is significant as migraines are common and debilitating in this age group.
AbbVie is conducting a clinical study titled ‘A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies.’ This study aims to assess the safety and effectiveness of ABBV-319 in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). The significance of this study lies in its potential to offer new treatment options for these aggressive and challenging cancers.
AbbVie is conducting a study titled ‘A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression.’ The study aims to assess the safety and efficacy of Mirvetuximab Soravtansine in treating these cancers, which are resistant to platinum-based therapies. This research is significant as it targets tumors with high folate receptor alpha expression, potentially offering a new treatment avenue for a challenging cancer type.
AbbVie is currently conducting a Phase 1 clinical study titled ‘A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers.’ The study aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of IMGN151 in patients with various recurrent gynecological cancers. This research is significant as it explores a novel treatment option for patients who are suitable for nonplatinum single-agent therapy.
AbbVie is currently conducting a study titled, A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp-Up Periods in Previously Untreated Subjects With CLL. The study aims to assess the safety of venetoclax when combined with obinutuzumab or acalabrutinib in treating chronic lymphocytic leukemia (CLL), the most common form of leukemia. This research is significant as it seeks to optimize treatment regimens for CLL, potentially improving patient outcomes.
AbbVie is conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy.’ The study aims to assess the safety and efficacy of upadacitinib, an oral medication, in treating moderate to severe hidradenitis suppurativa (HS) in patients unresponsive to anti-TNF therapy. This research is significant as it explores a potential new treatment avenue for HS, a painful inflammatory skin condition.
AbbVie has announced a new clinical study titled ‘Multi-Country, Cross-sectional Study to Characterize Real World Burden of Disease in Adolescent and Adult Patients With Alopecia Areata, Vitiligo or Hidradenitis Suppurativa (MEASURE AAVitHS)’. The study aims to assess the disease burden in a global population of adolescents and adults suffering from moderate to severe alopecia areata, non-segmental vitiligo, and hidradenitis suppurativa. This research is significant as it seeks to provide a comprehensive understanding of these conditions’ impact on patients’ lives.
AbbVie is conducting a clinical study titled ‘Early therapeUtic RespOnse and Predictivity of Long-term Effectiveness of Upadacitinib in Ulcerative Colitis (EUROPE)’ to evaluate the effectiveness of upadacitinib in treating ulcerative colitis (UC). The study aims to assess changes in disease activity in adult participants with UC, a condition that causes inflammation and bleeding in the colon. This research is significant as it could enhance treatment strategies for UC patients.
AbbVie is conducting a clinical study titled ‘A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP)’. The study aims to assess the effectiveness and safety of upadacitinib in adults with moderate-to-severe atopic dermatitis who have not responded adequately to dupilumab, a common treatment for this condition.
AbbVie is conducting a Phase 2, multicenter study titled ‘A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis.’ The study aims to evaluate the efficacy and safety of targeted therapies for rheumatoid arthritis, a chronic inflammatory disease. This research is significant as it seeks to improve treatment options for patients with moderate to severe rheumatoid arthritis who have not responded to previous therapies.
AbbVie’s latest clinical study, titled A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine, aims to assess the effectiveness, safety, and tolerability of Atogepant in preventing menstrual migraines. This study is significant as it addresses a specific type of migraine that affects many women globally.
AbbVie is conducting a Phase 2a multicenter, randomized study titled ‘A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn’s Disease.’ The study aims to evaluate the effectiveness and safety of targeted therapies for adults suffering from moderate to severe Crohn’s Disease, a chronic inflammatory condition of the digestive tract. This research is significant as current treatments may not be effective for all patients or may lose efficacy over time.
AbbVie is conducting a study titled ‘SUNRISE-UC’ to evaluate the effectiveness and safety of risankizumab in patients with moderate to severe ulcerative colitis (UC). The study aims to assess changes in disease activity in a real-world setting, highlighting its significance in providing practical insights into treatment outcomes.
AbbVie (ABBV) is conducting a clinical study titled ‘A Phase 1b Dose Escalation and Expansion Study of IMGN151 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Subjects With Gynecologic Cancers.’ The study aims to evaluate the safety and tolerability of IMGN151, an investigational drug, in treating gynecologic cancers. This research is significant as it explores new treatment avenues for these cancers, potentially improving patient outcomes.
AbbVie is conducting a Phase 2 study titled ‘A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Leucovorin, and Budigalimab as First-Line Treatment in Subjects With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA-977)’. The study aims to assess the safety and efficacy of ABBV-400, combined with other drugs, in treating advanced gastric and esophageal cancers.
AbbVie is currently conducting a cross-sectional study titled ‘Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China.’ The primary objective is to evaluate treatment patterns, healthcare resource utilization, and the burden of non-segmental vitiligo (NSV) among patients in China. This study is significant as it aims to provide insights into the real-world impact of NSV, potentially guiding future healthcare strategies.
Study Overview: AbbVie is spearheading a Phase 2 clinical trial titled ‘A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.’ The study aims to evaluate the safety and efficacy of combining carboplatin and mirvetuximab soravtansine in treating advanced-stage cancers that express folate receptor alpha. This research is significant as it targets a specific protein, potentially offering a more targeted cancer treatment.
AbbVie is conducting a clinical study titled SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Moderately to Severely Active SLE. The study aims to assess the safety and effectiveness of upadacitinib, an oral medication, in treating adults with moderate to severe systemic lupus erythematosus (SLE). This research is significant as it targets a challenging autoimmune disease affecting multiple organ systems.
AbbVie is conducting a Phase 1/2 open-label study to evaluate the safety and efficacy of Etentamig, an investigational drug for multiple myeloma (MM), a cancer affecting plasma cells in the blood. The study, titled A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects With Multiple Myeloma, aims to assess disease activity changes and adverse events in adult participants. This research is significant as it targets relapsed or refractory MM, a challenging condition with limited treatment options.
AbbVie is conducting a Phase 2 study titled A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects With Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED). The study aims to evaluate the change in disease activity in colorectal cancer patients receiving telisotuzumab adizutecan alone versus those receiving the standard of care. This research is significant as colorectal cancer is the third most common cancer worldwide.
AbbVie is conducting a Phase 3b clinical study titled ‘A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab.’ The study aims to evaluate the safety and efficacy of risankizumab versus vedolizumab in treating adults with moderate to severe ulcerative colitis who have not previously received targeted therapies. This research is significant as it could offer new insights into treatment options for this chronic inflammatory condition.
AbbVie is currently conducting a Phase 1 clinical study titled ‘A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers’. The study aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of IMGN151 in patients with recurrent endometrial, ovarian, fallopian tube, primary peritoneal, or cervical cancers.
AbbVie is conducting a clinical study titled ‘A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp-Up Periods in Previously Untreated Subjects With CLL.’ The study aims to assess the safety and efficacy of venetoclax combined with obinutuzumab or acalabrutinib in treating chronic lymphocytic leukemia (CLL), focusing on the risk of tumor lysis syndrome (TLS) and optimizing treatment initiation.
AbbVie has announced a new clinical study titled ‘Multi-Country, Cross-sectional Study to Characterize Real World Burden of Disease in Adolescent and Adult Patients With Alopecia Areata, Vitiligo or Hidradenitis Suppurativa (MEASURE AAVitHS)’. The study aims to assess the burden of disease in individuals with moderate to severe alopecia areata, non-segmental vitiligo, or hidradenitis suppurativa, highlighting its significance in understanding these conditions globally.
AbbVie has initiated a Phase 3b study titled ‘A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab’. The study aims to evaluate the safety and efficacy of risankizumab versus vedolizumab in adults with moderate to severe ulcerative colitis who have not previously received targeted therapies. This research is significant as it could offer new insights into treatment options for this condition.
AbbVie is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy.’ This study aims to assess the safety and efficacy of upadacitinib, an oral medication, in treating moderate to severe hidradenitis suppurativa (HS) in patients unresponsive to anti-TNF therapy. The study’s significance lies in potentially offering a new treatment option for HS, a painful inflammatory skin condition.
AbbVie is conducting a Phase 3b/4 clinical study titled ‘SWITCH-UP’ to evaluate the efficacy and safety of upadacitinib in adult participants with moderate-to-severe atopic dermatitis who have shown inadequate response to dupilumab. This study aims to provide critical data on the effectiveness of upadacitinib, an approved drug for atopic dermatitis, in improving patient outcomes.
AbbVie is currently recruiting participants for a Phase 2 study titled A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis. The study aims to evaluate the efficacy and safety of targeted therapies for rheumatoid arthritis, a chronic inflammatory disease. This research is significant as it explores new treatment avenues for patients who have not responded to existing therapies.
AbbVie is conducting a clinical study titled ‘Early therapeUtic RespOnse and Predictivity of Long-term Effectiveness of Upadacitinib in Ulcerative Colitis (EUROPE)’ to evaluate the effectiveness of Upadacitinib in treating ulcerative colitis (UC). The study aims to assess changes in disease activity in adult participants with UC, highlighting its significance in improving treatment outcomes for this inflammatory bowel disease.
AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine. The study aims to assess the efficacy, safety, and tolerability of atogepant, an investigational drug, for preventing menstrual migraines in adult women. This study is significant as it targets a specific type of migraine associated with the menstrual cycle, potentially offering relief to many affected individuals.
AbbVie is conducting a Phase 2a multicenter, randomized study titled A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn’s Disease. The study aims to evaluate the effectiveness and safety of targeted therapies for adults with moderate to severe Crohn’s Disease, a chronic inflammatory condition of the digestive tract.
AbbVie is conducting a study titled ‘SUNRISE-UC’ to evaluate the effectiveness and safety of Risankizumab in patients with moderate to severe ulcerative colitis. This real-world study aims to assess changes in disease activity, providing valuable insights into the treatment’s impact on this inflammatory bowel disease.
AbbVie has recently completed a Phase 3b clinical study titled ‘A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension.’ The study aimed to assess the duration of intraocular pressure-lowering effects and safety of Bimatoprost sustained release (SR) in patients with open-angle glaucoma or ocular hypertension who are not adequately managed with topical medications. This study is significant as it explores alternative treatment options for patients who struggle with current therapies.
AbbVie is conducting a Phase 1b clinical study titled A Phase 1b Dose Escalation and Expansion Study of IMGN151 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Subjects With Gynecologic Cancers. The study aims to evaluate the safety and tolerability of IMGN151, an investigational drug, in adult participants with gynecologic cancers. The study’s significance lies in its potential to offer new treatment options for these cancers.
AbbVie is conducting a Phase 2 clinical study titled ‘A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Leucovorin, and Budigalimab as First-Line Treatment in Subjects With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA-977)’. The study aims to assess the safety and efficacy of ABBV-400, combined with other drugs, in treating advanced gastric and esophageal cancers.
AbbVie is conducting a clinical study titled ‘Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China.’ The study aims to evaluate treatment patterns, healthcare resource utilization, and the burdens associated with non-segmental vitiligo (NSV) among patients in China. This research is significant as it seeks to provide insights into the real-world impact of NSV on patients’ lives.
AbbVie is spearheading a new clinical study titled A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. The study aims to evaluate the safety and efficacy of combining carboplatin with mirvetuximab soravtansine in treating advanced-stage cancers that express the folate receptor alpha (FRα). This research is significant as it targets a specific protein on cancer cells, potentially offering a more precise treatment option.
AbbVie is currently conducting a Phase 3 clinical study titled ‘SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Moderately to Severely Active SLE.’ The study aims to assess the safety and effectiveness of upadacitinib, an oral medication, in treating adults with moderate to severe systemic lupus erythematosus (SLE), a disease characterized by inflammation of multiple organ systems.
AbbVie is conducting a Phase 1/2 open-label study to evaluate the safety and efficacy of Etentamig, an investigational drug for multiple myeloma (MM). The study aims to assess changes in disease activity and adverse events in adult participants receiving Etentamig alone or in combination with other treatments.
AbbVie is conducting a Phase 2 study titled ‘A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects With Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED)’. The study aims to evaluate adverse events and changes in disease activity in colorectal cancer patients receiving either telisotuzumab adizutecan or the standard of care.
AbbVie is conducting a Phase 3b clinical study titled ‘A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab.’ The study aims to evaluate the safety and effectiveness of risankizumab versus vedolizumab in treating adult patients with moderate to severe ulcerative colitis who have not previously undergone targeted therapies. This research is significant as it could offer new insights into treatment options for ulcerative colitis, a chronic inflammatory bowel disease.
AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine. The study aims to assess the efficacy, safety, and tolerability of atogepant, an investigational drug, in preventing menstrual migraines in adult women. This study is significant as it addresses a common and debilitating condition that affects many women.
AbbVie is conducting a Phase 2a multicenter study titled A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn’s Disease. The study aims to evaluate the effectiveness and safety of targeted therapies for adults with moderate to severe Crohn’s Disease, a chronic inflammatory condition of the digestive tract. This research is significant as current treatments may not work for all patients or lose effectiveness over time.
AbbVie recently completed a Phase 3b clinical study titled ‘A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension.’ The study aimed to assess the duration of intraocular pressure-lowering effects and safety of Bimatoprost sustained release (SR) in patients with open-angle glaucoma or ocular hypertension who are not adequately managed with topical medications. This research is significant as it explores alternative treatments for patients who struggle with current options.
AbbVie has initiated a study titled ‘A Prospective, Real-World Study EvalUating the EffectiveNess and Safety of RISankizumab in PatiEnts With Ulcerative Colitis (SUNRISE-UC).’ The study aims to assess the change in disease activity in adult patients with moderate to severe ulcerative colitis using risankizumab, an approved treatment. This research is significant as it evaluates the drug’s effectiveness and safety in real-world clinical settings.
AbbVie is conducting a Phase 1b clinical study titled A Phase 1b Dose Escalation and Expansion Study of IMGN151 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Subjects With Gynecologic Cancers. The study aims to assess the safety and tolerability of IMGN151, an investigational drug, in adult participants with gynecologic cancers. This research is significant as it explores potential new treatments for these cancers.
AbbVie has initiated a Phase 2 clinical study titled ‘A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Leucovorin, and Budigalimab as First-Line Treatment in Subjects With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma’. The study aims to assess adverse events and efficacy of ABBV-400 combined with other drugs for treating advanced gastric cancers, potentially offering new treatment avenues.
AbbVie is conducting a Phase 3b clinical study titled A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab. The study aims to evaluate the safety and effectiveness of risankizumab versus vedolizumab in treating adults with moderate to severe ulcerative colitis who have not previously used targeted therapies. This research is significant as it may offer new insights into treatment options for this inflammatory bowel disease.
AbbVie is conducting a Phase 3 clinical study to evaluate the efficacy, safety, and tolerability of oral ubrogepant tablets for the acute treatment of migraine in children and adolescents aged 6-17. This study aims to address the significant burden of migraine in this age group by testing ubrogepant, a drug already approved for adults, in younger patients.
AbbVie is conducting a Phase 2 clinical study titled A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer. The study aims to assess the safety and efficacy of telisotuzumab adizutecan, an investigational drug, in combination with other approved treatments for metastatic colorectal cancer (mCRC). This research is significant as mCRC is the third most common cancer worldwide, and new treatments could improve patient outcomes.
AbbVie is conducting a Phase 3 clinical study titled ‘A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab With Open-Label Induction, Randomized Double-Blind Maintenance, and Open-Label Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) With Moderately to Severely Active Ulcerative Colitis.' The study aims to assess the movement, safety, and efficacy of Risankizumab in treating pediatric patients with ulcerative colitis, a chronic inflammatory bowel disease.
AbbVie is conducting a Phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of ABBV-324 in adults with hepatocellular cancer (HCC) or squamous-cell non-small cell lung cancer (LUSC). The study aims to assess adverse events and changes in disease activity when ABBV-324 is administered. This investigational drug is being compared to lenvatinib, a standard treatment, to determine its potential benefits.
AbbVie is conducting a Phase 1 pharmacokinetic study to evaluate the relative bioavailability of Risankizumab when administered subcutaneously using an on-body injector in healthy adults. The study aims to determine how effectively the drug is absorbed into the bloodstream when delivered by this method, which could enhance patient convenience and compliance.
AbbVie is conducting a Phase 3 study titled ‘A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma.’ The study aims to evaluate the efficacy of etentamig, an investigational drug, against standard therapies in treating relapsed or refractory multiple myeloma (R/R MM). This study is significant as it addresses a critical need for effective treatments in R/R MM, a challenging blood cancer.
AbbVie is conducting a Phase 3 clinical study titled ‘SELECT-SLE’ to evaluate the safety and efficacy of upadacitinib in adults with moderately to severely active Systemic Lupus Erythematosus (SLE). The study aims to assess adverse events and changes in disease activity, which are crucial for understanding the drug’s potential benefits for SLE patients.
AbbVie is conducting a Phase 3 study titled A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Alopecia Areata and at Least 25% Scalp Hair Loss. The study aims to assess the safety, effectiveness, and tolerability of Upadacitinib in Japanese participants with severe alopecia areata, a condition where the immune system attacks hair follicles, causing hair loss.
Study Overview: Pfizer and AbbVie are conducting a clinical study titled ‘A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AZTREONAM AND AVIBACTAM ± METRONIDAZOLE IN NEONATES AND INFANTS FROM BIRTH TO LESS THAN 9 MONTHS OF AGE WITH SUSPECTED OR CONFIRMED INFECTIONS DUE TO GRAM-NEGATIVE PATHOGENS REQUIRING INTRAVENOUS ANTIBIOTIC TREATMENT.’ The study aims to assess the safety and effects of the combination antibiotic aztreonam-avibactam (ATM-AVI) in treating gram-negative bacterial infections in newborns and infants.
Study Overview: AbbVie is conducting a Phase 2/3 study titled A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment. The study aims to assess the optimal dose, safety, and efficacy of the investigational drugs livmoniplimab and budigalimab for treating advanced HCC, a leading cause of cancer-related deaths globally.
AbbVie is conducting a Phase 3 clinical study titled ‘A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.’ The study aims to evaluate the efficacy and safety of telisotuzumab vedotin compared to docetaxel in treating non-squamous non-small cell lung cancer (NSCLC) in adults who have already undergone treatment. This research is significant as it seeks to improve treatment options for NSCLC, a prevalent and challenging cancer type.
AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. The study aims to assess the safety and efficacy of the drug upadacitinib in treating patients with moderate to severe hidradenitis suppurativa (HS) who have not responded to anti-TNF therapy. This research is significant as it could provide a new treatment option for HS, a painful inflammatory skin condition.
AbbVie is currently conducting a Phase 3b clinical study titled A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab. The study aims to evaluate the safety and effectiveness of risankizumab versus vedolizumab in adult patients with moderate to severe ulcerative colitis who have not previously received targeted therapies. This research is significant as it could offer new insights into treatment options for this inflammatory bowel disease.
AbbVie is conducting a study titled ‘A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism.’ The study aims to assess the safety and efficacy of Armour Thyroid versus synthetic T4 in treating primary hypothyroidism, focusing on patients stabilized on synthetic T4. This research is significant as it explores potential improvements in treatment options for hypothyroidism.
AbbVie is conducting a Phase 1/2 study titled A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor ABBV-453 Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma. The study aims to assess the safety and efficacy of the investigational drug ABBV-453, alone or in combination with other antimyeloma agents, in adult patients with relapsed/refractory multiple myeloma (MM). This research is significant as it addresses a critical need for new treatments in MM, a disease characterized by the growth of clonal plasma cells in the bone marrow.
AbbVie is conducting a study titled An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Budigalimab in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations. The study aims to assess the safety and efficacy of combining Telisotuzumab Adizutecan with Budigalimab in treating non-squamous non-small cell lung cancer (NSCLC), a leading cause of cancer-related deaths worldwide.
Study Overview: AbbVie is conducting a Phase 3 multicenter study titled A Phase 3 Multicenter Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Upadacitinib With Open-Label Induction, Randomized, Double-Blind Maintenance and Open-Label Long-Term Extension in Pediatric Subjects With Moderately to Severely Active Crohn’s Disease and Inadequate Response, Intolerance, or Medical Contraindications to Corticosteroids, Immunosuppressants, and/or Biologic Therapy. The study aims to assess the efficacy and safety of Upadacitinib in pediatric patients with Crohn’s Disease who have not responded adequately to other treatments.
AbbVie is conducting a clinical study titled ‘First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects With Relapsed or Refractory Multiple Myeloma.’ The study aims to evaluate the safety and toxicity of ABBV-453 in adults with relapsed or refractory multiple myeloma (R/R MM), focusing on adverse events and changes in disease activity.
AbbVie is conducting a Phase 3 study, officially titled A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-Takayasu). The study aims to assess the efficacy of upadacitinib combined with a corticosteroid taper regimen compared to a placebo in treating Takayasu Arteritis, a rare form of vasculitis. This study is significant as it explores new treatment options for this challenging condition.
AbbVie is conducting a Phase 3 study titled A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy. The study aims to assess the safety and effectiveness of upadacitinib, an approved drug for immune-mediated inflammatory diseases, in treating non-segmental vitiligo (NSV), a chronic autoimmune disease.
AbbVie is conducting a Phase 1 clinical study titled ‘A Phase 1 Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088’. The primary aim is to evaluate the safety, tolerability, and pharmacokinetics of ABBV-1088 in healthy adults, including Western, Han-Chinese, and Japanese participants. Additionally, the study examines the interaction between ABBV-1088 and itraconazole in Western participants, which is significant for understanding potential drug interactions.
AbbVie is conducting a Phase 2 study titled A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC. The study aims to assess the safety, optimal dosing, and efficacy of the combination treatment in patients with advanced HCC, a leading cause of cancer-related deaths globally.
AbbVie is conducting a clinical study titled A Multicenter, Evaluator Blinded, Randomized Study to Evaluate the Safety and Effectiveness of HArmonyCa Lidocaine Compared to Restylane® Perlane® Lidocaine for Restoration and/or Creation of Mid-face Volume. The study aims to assess the safety and effectiveness of HArmonyCa Lidocaine injectable gel, a dermal filler designed for facial soft tissue augmentation, compared to an existing product, Restylane® Perlane® Lidocaine. This study is significant as it addresses the common effects of aging and environmental exposure on skin appearance.
AbbVie is conducting a clinical study titled ‘A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies’ to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-525 in adult patients with B-cell malignancies. This study is significant as it explores a novel treatment option for these types of cancers.
AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine. The study aims to assess the efficacy, safety, and tolerability of Atogepant in preventing menstrual migraines compared to a placebo. This study is significant as menstrual migraines affect many women, and effective preventive treatments are limited.
AbbVie has completed a significant clinical study titled ‘Special Drug Use Results Survey of Safety and Efficacy of Long-term (104 Weeks) Use of Duodopa Enteral Solution in Patients With Parkinson’s Disease in Actual Usage Condition.’ The study aimed to evaluate the safety and efficacy of Duodopa, an enteral solution, for long-term use in Parkinson’s disease patients, highlighting its potential impact on treatment protocols.
AbbVie, in collaboration with REGENXBIO Inc., is conducting a pivotal Phase 3 clinical study titled ‘A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD.’ The study aims to assess the efficacy and safety of RGX-314, a novel gene therapy for neovascular age-related macular degeneration (wet AMD), which is a leading cause of vision loss. This therapy could potentially offer a one-time treatment alternative to current anti-VEGF therapies, which require frequent injections.
AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of OnabotulinumtoxinA Purified Neurotoxin Complex for the Treatment of Moderate to Severe Forehead Lines in Japan. The study aims to assess the safety and efficacy of onabotulinumtoxinA in treating moderate to severe forehead lines in Japanese adults, highlighting its significance in aesthetic medicine.
AbbVie is conducting a Phase 1/1b study titled ‘A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors.’ The study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-399, also known as Telisotuzumab vedotin, in patients with advanced solid tumors likely to express c-Met. This study is significant as it explores potential new treatments for challenging cancer types.
AbbVie is conducting a clinical study titled ‘A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis.’ The study aims to evaluate the safety and efficacy of risankizumab in patients with ulcerative colitis who responded to prior induction treatment. This research is significant as it may offer new therapeutic options for managing ulcerative colitis.
AbbVie is conducting a clinical study titled ‘A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies’. The study aims to assess the safety and efficacy of ABBV-319 in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL), which are aggressive forms of cancer affecting the immune system.
AbbVie’s ongoing clinical study, officially titled ‘A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma,’ aims to evaluate the safety, tolerability, and efficacy of these drug combinations in treating relapsed or refractory multiple myeloma. This study is significant as it explores potential new treatment options for this challenging condition.
AbbVie is conducting a Phase 1b/2 clinical study titled ‘IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia.’ The study aims to evaluate the safety and antileukemia activity of IMGN632, alone or in combination with azacitidine and venetoclax, in patients with CD123-positive acute myeloid leukemia (AML). This research is significant as it explores new treatment avenues for AML, a challenging blood cancer.
AbbVie is conducting a Phase 2 study to evaluate the safety and efficacy of lutikizumab (ABT-981) in adults with moderate to severe hidradenitis suppurativa (HS) who have not responded to anti-TNF therapy. The study aims to address the unmet medical need for effective treatment in this patient group.
AbbVie is conducting a significant study titled A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn’s Disease. The study aims to evaluate the efficacy and safety of Risankizumab as a maintenance therapy for individuals with moderate to severe Crohn’s Disease, who have previously responded to induction treatment. This research is crucial as it could lead to improved treatment options for Crohn’s Disease patients.
AbbVie is conducting a clinical study titled ‘A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP)’. The study aims to assess the efficacy and safety of upadacitinib in adults with moderate to severe atopic dermatitis who have not responded adequately to dupilumab. This research is significant as it targets a population with limited treatment options.
AbbVie is conducting a study titled ‘Venetoclax AML Observational Real-World Study of Treatment-naïve Patients Ineligible for Intensive Chemotherapy in Switzerland & Austria.’ The study aims to assess the effectiveness of Venetoclax in treating acute myeloid leukemia (AML) in adults who cannot undergo intensive chemotherapy. This research is significant as AML is the most common acute leukemia in adults, and finding effective treatments for those ineligible for intensive therapy is crucial.
AbbVie (ABBV) has initiated a clinical study titled ‘A ProspeCtive ObseRvatioNal Study of Atogepant Effectiveness in Routine Clinical Practice’ to evaluate the real-world effectiveness of atogepant in treating migraines in adults. This study aims to assess how well atogepant, an approved preventive treatment for migraines, performs in everyday clinical settings, involving approximately 1,000 participants globally.
AbbVie is conducting a Phase 3 study titled ‘A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects With Ulcerative Colitis.’ The study aims to assess the long-term safety and efficacy of Upadacitinib in patients with ulcerative colitis who have not responded to previous treatments or have completed prior studies. This research is significant as it could offer new hope for patients with limited treatment options.
AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn’s Disease. The study aims to assess the safety and effectiveness of risankizumab, a subcutaneous treatment, in adults with moderate to severe Crohn’s disease. This research is significant as it could offer a new therapeutic option for managing this chronic condition.
AbbVie is conducting a study titled ‘Real World Utilization of Upadacitinib in Adult and Adolescent Patients Living With Moderate to Severe Atopic Dermatitis (AD-VISE)’ to assess the real-world use, safety, and effectiveness of the drug upadacitinib in treating atopic dermatitis in individuals aged 12 and older. This study aims to provide insights into the drug’s usage patterns and outcomes outside of a clinical trial setting, which is crucial for understanding its long-term impact and effectiveness.
AbbVie is conducting a Phase 2 study titled A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Budigalimab and/or ABBV-382 in People Living With HIV on Stable Antiretroviral Therapy Undergoing Analytical Treatment Interruption. The study aims to assess changes in disease activity, adverse events, and drug pharmacokinetics in adults with HIV.
AbbVie is conducting a study titled ‘Prospective Non-Interventional Study to Investigate the Durable Effectiveness of Risankizumab Using Digital and Remote Evaluation Tools in Moderate to Severe Psoriasis Patients – prIMMa Study.’ The study aims to assess the effectiveness of risankizumab in alleviating symptoms of moderate to severe psoriasis, a condition that significantly impacts quality of life.
AbbVie is conducting a study titled ‘A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression.’ The study aims to assess the safety and efficacy of Mirvetuximab Soravtansine in patients with these types of cancers, focusing on those with high folate receptor-alpha expression. This research is significant as it targets a challenging cancer type that is resistant to platinum-based treatments.
AbbVie is currently conducting a Phase 2 multicenter, randomized study titled A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Active Psoriatic Arthritis. The study aims to evaluate the efficacy and safety of targeted therapies in treating active psoriatic arthritis, focusing on changes in disease symptoms.
AbbVie is conducting a Phase 2 clinical study titled ‘A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.’ The study aims to evaluate the safety and efficacy of combining carboplatin with mirvetuximab soravtansine in treating advanced-stage cancers expressing folate receptor alpha. This research is significant as it targets a specific protein on cancer cells, potentially offering a more targeted treatment approach.
AbbVie is conducting a Phase 3 clinical study to evaluate the safety and effectiveness of oral ubrogepant tablets for treating acute migraine in children and adolescents aged 6-17. This randomized, double-blind, placebo-controlled study aims to assess adverse events, disease activity, and pharmacokinetics of ubrogepant, a drug already approved for adults, in younger patients.
AbbVie is conducting a Phase 3 clinical study titled A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Alopecia Areata and at Least 25% Scalp Hair Loss. This study aims to assess the safety, effectiveness, and tolerability of upadacitinib in treating severe alopecia areata (AA) in adolescents and adults in Japan, a condition characterized by immune system-induced hair loss.
AbbVie is conducting a Phase 3b clinical study titled Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects With Moderate to Severe Ulcerative Colitis Who Are Naïve to Targeted Therapies. The study aims to evaluate the safety and effectiveness of risankizumab compared to vedolizumab in treating moderate to severe ulcerative colitis (UC) in adults who have not previously received targeted therapies. This research is significant as it explores potential new treatment options for UC, a chronic inflammatory bowel disease.
AbbVie is conducting a Phase 1 clinical study titled ‘A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors.’ The study aims to evaluate the safety and efficacy of ABBV-CLS-579, both as a standalone treatment and in combination with other agents, for patients with advanced tumors. This research is significant as it seeks to establish a new treatment option for patients with limited alternatives.
AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. The study aims to assess the safety and efficacy of upadacitinib, an oral medication, in treating moderate to severe hidradenitis suppurativa (HS) in patients who have not responded to anti-TNF therapy. This study is significant as it explores a potential new treatment for HS, a painful inflammatory skin condition.
AbbVie is conducting a Phase 2 study titled ‘A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer.’ The study aims to evaluate the safety and efficacy of telisotuzumab adizutecan, an investigational drug, in combination with other treatments for metastatic colorectal cancer (mCRC), a prevalent cancer type worldwide.
AbbVie is conducting a Phase 3 multicenter study titled ‘A Phase 3 Multicenter Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Upadacitinib With Open-Label Induction, Randomized, Double-Blind Maintenance and Open-Label Long-Term Extension in Pediatric Subjects With Moderately to Severely Active Crohn’s Disease and Inadequate Response, Intolerance, or Medical Contraindications to Corticosteroids, Immunosuppressants, and/or Biologic Therapy.’ The study aims to assess the safety and effectiveness of Upadacitinib in treating pediatric patients with moderate to severe Crohn’s Disease who have not responded well to other treatments.
AbbVie is conducting a clinical study titled An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Budigalimab in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations. The study aims to assess the safety and efficacy of combining Telisotuzumab Adizutecan and Budigalimab in treating non-squamous non-small cell lung cancer (NSCLC), a leading cause of cancer-related deaths globally.
AbbVie is currently conducting a clinical study titled ‘A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor ABBV-453 Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma.’ The study aims to assess the safety and disease activity changes of ABBV-453, an investigational drug for relapsed/refractory multiple myeloma (R/R MM), in adult participants. This research is significant as it targets a challenging plasma cell disease affecting bone marrow.
AbbVie is conducting a Phase 1 clinical trial titled A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumors. The study aims to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and determine the maximum tolerated dose or recommended Phase 2 dose when used alone or with ABBV-181 in patients with advanced solid tumors.
AbbVie is conducting a Phase 1 clinical study titled A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Etentamig (ABBV-383) Monotherapy in Japanese Subjects With Relapsed or Refractory Multiple Myeloma (4L+ RRMM Monotherapy Study). The study aims to assess adverse events and changes in disease state in adult participants with relapsed or refractory multiple myeloma (R/R MM) in Japan, highlighting its significance in addressing this incurable disease.
AbbVie is conducting a study titled ‘Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson’s Disease’ to evaluate the safety and efficacy of Duodopa for long-term use in real-world settings. The primary objective is to understand how this treatment performs over 104 weeks in patients with Parkinson’s disease.
AbbVie is currently recruiting participants for a study titled ‘Effectiveness and Safety of Venetoclax in Combination With Azacitidine in Patients With Acute Myeloid Leukemia in Real Life Clinical Practice.’ This study aims to evaluate the effectiveness of venetoclax combined with azacitidine in treating acute myeloid leukemia (AML) in adults in Colombia. The significance of this study lies in its focus on real-world clinical practice, potentially offering insights into treatment efficacy outside controlled clinical environments.
AbbVie is conducting a clinical study titled ‘Mass Balance Study of [14C] ABBV-932 Following Single Oral Dose Administration in Healthy Male Volunteers’. The primary goal is to evaluate the safety and tolerability of the drug ABBV-932 in healthy adult male participants, which is crucial for its future development and potential therapeutic applications.
AbbVie has initiated a clinical study titled A Prospective, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Subjects With Glaucoma. The study aims to assess the safety and effectiveness of the XEN63 gel stent in managing intraocular pressure in glaucoma patients, a leading cause of blindness globally.
AbbVie is conducting a Phase 3 study titled A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. The study aims to assess the safety and effectiveness of upadacitinib in treating moderate to severe hidradenitis suppurativa (HS) in patients who have not responded to anti-TNF therapy. This research is significant as it could offer a new treatment option for HS, a painful inflammatory skin condition.
AbbVie is conducting a Phase 3 clinical study to evaluate the efficacy, safety, and tolerability of ubrogepant for the preventive treatment of menstrual migraine. This study, titled ‘A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine With an Open-Label Extension,’ aims to assess adverse events and changes in disease activity among adult participants with menstrual migraines.
AbbVie and Genmab are conducting a Phase 3 clinical trial to evaluate the safety and efficacy of a new treatment combination for follicular lymphoma, a common type of B-cell cancer. The study, titled ‘A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2),’ aims to assess adverse events and changes in disease activity in adults with previously untreated follicular lymphoma.
The recent clinical study update from AbbVie and Genmab focuses on evaluating the efficacy and safety of Epcoritamab, with or without Lenalidomide, as a first-line treatment for elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who are ineligible for anthracycline therapy. Officially titled ‘Efficacy and Safety of Epcoritamab Monotherapy and in Combination With Lenalidomide as First-line Therapy for Anthracycline-ineligible Diffuse Large B-Cell Lymphoma Patients,’ this Phase 2 trial aims to provide alternative therapeutic options for this patient demographic.
AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine. The study aims to assess the efficacy, safety, and tolerability of atogepant, an investigational drug, in preventing menstrual migraines. This study is significant as menstrual migraines can severely impact quality of life, and effective preventive treatments are needed.
AbbVie and Genmab are conducting a Phase 1/2 clinical trial titled ‘A Phase 1/2, Open-label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma.’ The study aims to evaluate the safety, dosage, and efficacy of epcoritamab, a promising antibody treatment for B-cell lymphoma. This trial is significant as it explores new therapeutic options for patients with limited treatment choices.
Pfizer Inc. and AbbVie are conducting a clinical study titled ‘A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AZTREONAM AND AVIBACTAM ± METRONIDAZOLE IN NEONATES AND INFANTS FROM BIRTH TO LESS THAN 9 MONTHS OF AGE WITH SUSPECTED OR CONFIRMED INFECTIONS DUE TO GRAM-NEGATIVE PATHOGENS REQUIRING INTRAVENOUS ANTIBIOTIC TREATMENT.’ The study aims to assess the safety and effects of the combination drug Aztreonam-Avibactam (ATM-AVI) in treating gram-negative bacterial infections in infants and newborns.
The recent clinical study update from AbbVie and Genmab focuses on evaluating the safety and effectiveness of a new treatment for relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL). Officially titled A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin, the study aims to compare the novel combination of epcoritamab and lenalidomide against the standard treatment regimen of rituximab, gemcitabine, and oxaliplatin. This study is significant as it targets a rare and aggressive form of cancer, potentially offering new hope for patients.
AbbVie and Genmab are conducting a clinical study titled ‘Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) in Japanese Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma.’ The study aims to assess the safety and efficacy of epcoritamab in Japanese patients with relapsed or refractory B-cell lymphomas. This trial is significant as it explores a potential new treatment avenue for a challenging cancer type.
AbbVie is conducting a first-in-human study titled ‘First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies.’ This study aims to assess the safety and effectiveness of ABBV-101 in treating various subtypes of non-Hodgkin’s lymphoma (NHL), including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL).
AbbVie is currently conducting a Phase 3 clinical study titled A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis. The study aims to evaluate the safety and efficacy of oral upadacitinib compared to subcutaneous dupilumab in treating moderate to severe atopic dermatitis in children who require systemic therapy.
AbbVie is currently recruiting participants for a Phase 2 study titled ‘A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Active Psoriatic Arthritis.’ The study aims to evaluate the efficacy and safety of targeted therapies, specifically risankizumab and lutikizumab, in treating active psoriatic arthritis and assessing changes in disease symptoms. This research is significant as it could lead to improved treatment options for individuals suffering from this chronic condition.
AbbVie and Genmab are collaborating on a clinical study titled ‘Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)’. This Phase 1b/2 trial aims to evaluate the safety and preliminary efficacy of epcoritamab, alone or in combination with other treatments, for patients with B-NHL. The study is significant as it seeks to establish an effective treatment regimen for this type of lymphoma.
AbbVie is currently conducting a Phase 3 clinical study titled A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa. The study aims to assess the disease activity and safety of Lutikizumab, an investigational drug, in treating moderate to severe Hidradenitis Suppurativa (HS), a chronic inflammatory skin condition.
AbbVie is conducting a Phase 3b study titled ‘A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab.’ This study aims to evaluate the safety and effectiveness of risankizumab versus vedolizumab in treating adults with moderate to severe ulcerative colitis who have not previously received targeted therapies. The study’s significance lies in its potential to offer new insights into treatment options for this inflammatory bowel disease.
AbbVie is conducting a Phase 2 clinical study titled ‘A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer.’ The study aims to assess the safety and efficacy of telisotuzumab adizutecan in combination with other drugs for treating metastatic colorectal cancer (mCRC), a prevalent cancer worldwide.
AbbVie is currently conducting a Phase 1/2 open-label study to evaluate the safety and efficacy of Etentamig, a new investigational drug, for treating multiple myeloma. The study aims to assess changes in disease activity and adverse events in adult participants receiving Etentamig alone or in combination with other treatments like Daratumumab, Lenalidomide, and Carfilzomib. This research is significant as it targets relapsed or refractory multiple myeloma, a challenging condition to treat.
AbbVie and Genmab are conducting a Phase 1b/2 clinical study to evaluate the safety and tolerability of epcoritamab, a subcutaneous investigational drug, in combination with various anti-neoplastic agents for treating Non-Hodgkin Lymphoma (NHL). The study aims to assess adverse events and changes in disease activity among approximately 565 adult participants globally.
AbbVie is conducting a clinical study titled ‘An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients With Open Angle Glaucoma or Ocular Hypertension.’ The study aims to assess the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients who have previously participated in related Phase 3 and Phase 4 studies. This research is significant as it could provide insights into the prolonged use of Bimatoprost SR, potentially impacting treatment protocols for glaucoma and ocular hypertension.
AbbVie is conducting a Phase 1 clinical study titled ‘A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers.’ The study aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of IMGN151 in adult patients with various recurrent gynecological cancers. This research is significant as it explores a potential new treatment option for patients who are suitable for nonplatinum single-agent therapy.
AbbVie has initiated a Phase 2 clinical study to evaluate the safety and efficacy of ABBV-CLS-628, an investigational drug for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). The study aims to assess adverse events and the drug’s effectiveness in adult participants with ADPKD, a common genetic cause of kidney disease characterized by fluid-filled cysts in the kidneys.
AbbVie is conducting a Phase 3 clinical study titled ‘A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine.’ The study aims to assess the efficacy, safety, and tolerability of Atogepant, an investigational drug, in preventing menstrual migraines in adult women. This study is significant as it addresses a specific type of migraine that affects women around their menstrual cycle.
AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine With an Open-Label Extension. The study aims to assess the safety and effectiveness of ubrogepant in treating menstrual migraine, a condition characterized by migraine attacks around the menstrual period.
The recent clinical study update from AbbVie and Genmab focuses on a Phase 1/2 trial titled ‘A Phase 1/2, Open-label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma.’ The study aims to evaluate the safety, dosage, and efficacy of epcoritamab in treating B-cell lymphoma, a significant step in addressing relapsed or refractory cases.
AbbVie and Genmab are conducting a Phase 3 clinical study to evaluate the safety and efficacy of epcoritamab plus lenalidomide compared to rituximab plus gemcitabine and oxaliplatin in treating relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL). This study is significant as it explores new treatment options for this aggressive form of cancer, potentially improving patient outcomes.
Pfizer and AbbVie are collaborating on a clinical study titled ‘A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AZTREONAM AND AVIBACTAM ± METRONIDAZOLE IN NEONATES AND INFANTS FROM BIRTH TO LESS THAN 9 MONTHS OF AGE WITH SUSPECTED OR CONFIRMED INFECTIONS DUE TO GRAM-NEGATIVE PATHOGENS REQUIRING INTRAVENOUS ANTIBIOTIC TREATMENT.’ The study aims to assess the safety and effects of the combination drug aztreonam-avibactam (ATM-AVI) in treating bacterial infections in infants, a significant step in addressing antibiotic resistance.
The recent clinical study update from AbbVie and Genmab focuses on the safety and preliminary efficacy of Epcoritamab in Japanese patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL). Officially titled ‘Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) in Japanese Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma,’ this Phase 1/2 trial aims to determine the maximum tolerated dose and recommended Phase-2 dose, while establishing the safety profile of Epcoritamab.
AbbVie is conducting a first-in-human study to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-101, a BTK degrader, in adults with B-cell malignancies. This study focuses on relapsed or refractory non-Hodgkin’s lymphomas, including chronic lymphocytic leukemia and other subtypes. The study aims to determine the maximum tolerated dose and assess changes in disease activity.
AbbVie and Genmab are conducting a global Phase 2 trial to evaluate the efficacy and safety of epcoritamab, both as a standalone treatment and in combination with lenalidomide, for elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. This study, titled ‘Efficacy and Safety of Epcoritamab Monotherapy and in Combination With Lenalidomide as First-line Therapy for Anthracycline-ineligible Diffuse Large B-Cell Lymphoma Patients,’ aims to provide new treatment options for this patient group.
AbbVie is conducting a Phase 3b, multicenter, randomized, open-label study to evaluate the efficacy and safety of risankizumab compared to vedolizumab in treating adult patients with moderate to severe ulcerative colitis who have not previously received targeted therapies. This study is significant as it aims to provide insights into better treatment options for ulcerative colitis, a chronic inflammatory bowel disease.
AbbVie and Genmab are conducting a Phase 3 clinical trial to evaluate the safety and efficacy of a new treatment combination for follicular lymphoma, a common B-cell cancer. The study, titled ‘EPCORE™FL-2,’ aims to assess the effects of combining subcutaneous epcoritamab with intravenous rituximab and oral lenalidomide (R2) compared to standard chemoimmunotherapy. This research is significant as follicular lymphoma is typically incurable with conventional treatments, and recurrence is common.